Asael Herman | CTO
Emendo Biotherapeutics

Asael Herman, CTO, Emendo Biotherapeutics

Asael  is Emendo’s CTO. He has over 20 years of experience in protein engineering and is an expert in the directed molecular evolution approach. Prior to joining Emendo he led the R&D of Smartzyme Biopharma. He formerly was the VP of R&D at Biolojic Design, an antibodies engineering company. Prior to that he served as Head of Enzyme Engineering at Bio Architecture Lab, a start-up synthetic biology and biofuels firm. Dr. Herman holds a PhD in Bio chemistry and Molecular Biology from the Hebrew University and further trained in protein engineering with Prof. Dan Tawfik at the Weizmann Institute and Prof. Larry Loeb at the University of Washington.


Conference Day 2 - Wednesday 1st April 2020 @ 14:20

Target optimized variants of CRISPR associated nuclease enables allele-specific gene-editing therapy

  • High precision genome editing is key when developing a genetic cure for congenital diseases.
  • To achieve high precision, optimization of the nuclease per target sequence is a must. Our approach to achieving high precision editing with no off-targets is to employ advanced protein engineering using directed evolution.
  • The approach we present here is novel and broad; it opens up unlimited opportunities for gene editing therapy in cases of dominant negative mutations, compound heterozygous mutations and haploinsufficiency.

Conference Day 2 - Wednesday 1st April 2020 @ 15:00

Panel discussion: Exploring advances in gene editing technology, research and ethical questions

last published: 04/Jun/20 08:25 GMT

back to speakers